


Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 (Currently amended). A method for treating diabetes type II, comprising administering to a human or other mammal in need thereof:

an effective amount of a compound according to formula I



as well as a tautomer, geometrical isomer, optically active form as enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt thereof, wherein

G is a pyrimidinyl group;

L is an C₁-C₆-alkoxy, an amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom selected from the group consisting of N, O, and S; and


R¹ is selected from the group consisting of hydrogen, sulfonyl, amino, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl or C₁-C₆-alkoxy, aryl, halogen, cyano and hydroxy, ~~and~~

~~at least one supplementary drug selected from the group consisting of insulin, aldose reductase inhibitors, alpha-glucosidase inhibitors, sulfonyl urea agents, biguanides, thiazolidines, PPARs agonists, and GSK-3 inhibitors.~~

2 (Previously presented). The method according to claim 1, wherein the metabolic disorder is diabetes type II.

3 (Previously presented). The method according to claim 1, wherein, in the compound, R^1 is H or C_1 - C_3 alkyl.

4 (Previously presented). The method according to claim 1, wherein the compound has any of formulae (Ia), (Ia') or (Ia''):



wherein R^1 is selected from the group consisting of hydrogen, sulfonyl, amino, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkoxy, aryl, halogen, cyano, and hydroxy; and

L is an amino group of the formula $-NR^3R^4$, wherein R^3 and R^4 are each independently from each other H, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, (wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl, heterocycloalkyl, aryl or heteroaryl group), C_1 - C_6 -alkyl aryl, C_1 - C_6 -alkyl heteroaryl, C_1 - C_6 -alkenyl aryl, C_1 - C_6 -alkenyl heteroaryl, C_1 - C_6 -alkynyl aryl, C_1 - C_6 -alkynyl heteroaryl, C_1 - C_6 -alkyl cycloalkyl, C_1 - C_6 -alkyl heterocycloalkyl, C_1 - C_6 -alkenyl cycloalkyl, C_1 - C_6 -alkenyl heterocycloalkyl, C_1 - C_6 -alkynyl cycloalkyl, C_1 - C_6 -alkynyl heterocycloalkyl; or


R^3 and R^4 may form a ring together with the nitrogen to which they are bound.

5(Previously presented). The method according to claim 4, wherein, in the compound, R^3 is hydrogen or a methyl or ethyl or propyl group and R^4 is selected from the group consisting of a (C_1-C_6) -alkyl, C_1 - C_6 -alkyl-aryl, C_1 - C_6 -alkyl-heteroaryl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, and 4-8 membered saturated or unsaturated cycloalkyl.

6(Previously presented). The method according to claim 4, wherein, in the compound, R^3 and R^4 form an

optionally substituted piperazine or a piperidine or a morpholine or a pyrrolidine ring together with the nitrogen to which they are bound, whereby said optional substituent is selected from the group consisting of a C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, (wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl, heterocycloalkyl, aryl or heteroaryl group), C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, C₁-C₆-alkenyl aryl, C₁-C₆-alkenyl heteroaryl, C₁-C₆-alkynyl aryl, C₁-C₆-alkynyl heteroaryl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl, C₁-C₆-alkenyl cycloalkyl, C₁-C₆-alkenyl heterocycloalkyl, C₁-C₆-alkynyl cycloalkyl, and C₁-C₆-alkynyl heterocycloalkyl.

7 (Previously presented). The method according to claim 5, wherein, in the compound, L is selected from the group consisting of:



wherein n is 1 to 10, and

R^5 and $R^{5'}$ are independently selected from each other from the group consisting of H, C_1 - C_{10} alkyl, aryl or hetero-aryl, C_1 - C_6 alkyl-aryl, and C_1 - C_6 -alkyl-heteroaryl.

8 (Previously presented). The method according to claim 1, wherein the compound is selected from the group consisting of:

1,3-benzothiazol-2-yl(2,6-dimethoxy-4-pyrimidinyl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(1H-imidazol-5-yl)ethyl]amino}-4-pyrimidinyl)acetonitrile;

1,3-benzothiazol-2-yl[2-(1-piperazinyl)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl[2-(4-benzyl-1-piperidinyl)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl[2-(4-morpholinyl)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl[2-(methylamino)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl(2-{4-[2-(4-morpholinyl)ethyl]-1-piperazinyl}-4-pyrimidinyl)-acetonitrile;

1,3-benzothiazol-2-yl{2-[4-(benzyloxy)-1-piperidinyl]-4-pyrimidinyl}acetonitrile;

1,3-benzothiazol-2-yl[2-(4-hydroxy-1-piperidinyl)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(dimethylamino)ethyl]amino}-4-pyrimidinyl)acetonitrile;

1,3-benzothiazol-2-yl[2-(dimethylamino)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl{2-[(2-methoxyethyl)amino]-4-pyrimidinyl}acetonitrile;

1,3-benzothiazol-2-yl{2-[(2-hydroxyethyl)amino]-4-pyrimidinyl}acetonitrile;

1,3-benzothiazol-2-yl[2-(propylamino)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl(2-{[3-(1H-imidazol-1-yl)propyl]amino}-4-pyrimidinyl)acetonitrile;

1,3-benzothiazol-2-yl[2-(1-pyrrolidinyl)-4-pyrimidinyl]acetonitrile;

1,3-benzothiazol-2-yl{2-[(2-phenylethyl)amino]-4-pyrimidinyl}acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(2-pyridinyl)ethyl]amino}-4-pyrimidinyl)acetonitrile;

1,3-benzothiazol-2-yl{2-[(2-pyridinylmethyl)amino]-4-pyrimidinyl}acetonitrile;

1,3-benzothiazol-2-yl{2-[4-(1H-1,2,3-benzotriazol-1-yl)-1-piperidinyl]-4-pyrimidinyl}acetonitrile;

1,3-benzothiazol-2-yl{2-[4-(2-pyrazinyl)-1-piperazinyl]-4-pyrimidinyl}acetonitrile;

1,3-benzothiazol-2-yl{2-[4-(2-pyrimidinyl)-1-piperazinyl]-4-pyrimidinyl}acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl)acetonitrile;

1,3-benzothiazol-2-yl(5-bromo-2-{[2-(dimethylamino)ethyl]amino}-4-pyrimidinyl)-acetonitrile;

1,3-benzothiazol-2-yl{2-[(2-morpholin-4-ylethyl)amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl[2-(4-{3-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)pyrimidin-4-
yl]acetonitrile;

1,3-benzothiazol-2-yl(2-{[3-(2-oxopyrrolidin-1-
yl)propyl]amino}pyrimidin-4-yl)-acetonitrile;

1,3-benzothiazol-2-yl(2-{methyl[3-
(methylanino)propyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[3-(4-methylpiperazin-1-
yl)propyl]amino}pyrimidin-4-yl)-acetonitrile;

1,3-benzothiazol-2-yl{2-[(3-morpholin-4-
ylpropyl)amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(1-methyl-1H-imidazol-4-
yl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(1H-indol-3-
yl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(4-
hydroxyphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

tert-butyl ({4-[1,3-benzothiazol-2-
yl(cyano)methyl]pyrimidin-2-yl}amino)acetate

{2-[(3-aminopropyl)amino]pyrimidin-4-yl}(1,3-
benzothiazol-2-yl)acetonitrile;

{2-[(2-aminoethyl)amino]pyrimidin-4-yl}(1,3-benzothiazol-
2-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[3-(dimethylamino)propyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl{2-[(2-piperidin-1-ylethyl)amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(1-methyl-1H-imidazol-5-yl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl[2-(benzylamino)pyrimidin-4-yl]acetonitrile;

isopropyl 3-({4-[1,3-benzothiazol-2-yl(cyano)methyl]pyrimidin-2-yl}amino)propanoate;

1,3-benzothiazol-2-yl{2-[(3-hydroxypropyl)amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl{2-[(pyridin-3-ylmethyl)amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl{2-[(pyridin-4-ylmethyl)amino]pyrimidin-4-yl}acetonitrile;

tert-butyl 4-[2-({4-[1,3-benzothiazol-2-yl(cyano)methyl]pyrimidin-2-yl}amino)-ethyl]phenylcarbamate;

(2-{[2-(4-aminophenyl)ethyl]amino}pyrimidin-4-yl)(1,3-benzothiazol-2-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(3,4-dimethoxyphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl (2-{[2-(3-methoxyphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl (2-{[2-(2-fluorophenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl [2-({2-[3-(trifluoromethyl)phenyl]ethyl}amino)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl {2-[(2-hydroxy-2-phenylethyl) amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl {2-[(2-{[3-(trifluoromethyl)pyridin-2-yl]amino}ethyl) amino]-pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl (2-{[2-(3-chlorophenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl (2-{[2-(3,4-dichlorophenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl (2-{[2-(4-methoxyphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl (2-{[2-(4-methylphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl (2-{[2-(3-fluorophenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl (2-{[2-(4-phenoxyphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(2-phenoxyphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(4-bromophenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl{2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl{2-[(2-{4-[hydroxy(oxido)amino]phenyl}ethyl)amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl(2-{[2-(1H-1,2,4-triazol-1-yl)ethyl]amino}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl(2-{[3-(1H-pyrazol-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile;

4-[2-({4-[1,3-benzothiazol-2-yl(cyano)methyl]pyrimidin-2-yl}amino)ethyl]benzene-sulfonamide;

{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]acetonitrile;

1,3-benzothiazol-2-yl{2-[(1H-tetraazol-5-ylmethyl)amino]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl[2-(benzyloxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl{2-[(4-pyridin-3-ylbenzyl)oxy]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl[2-(pyridin-4-ylmethoxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl[2-(pyridin-2-ylmethoxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl[2-(3-pyridin-2-ylpropoxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl{2-[(4-methoxybenzyl)oxy]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl[2-(pyridin-3-ylmethoxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl{2-[2-(4-methoxyphenyl)ethoxy]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl[2-([1,1'-biphenyl]-3-ylmethoxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl{2-[(3,4,5-trimethoxybenzyl)oxy]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl{2-[(3,4-dichlorobenzyl)oxy]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl[2-({3-[(dimethylamino)methyl]benzyl}oxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl{2-[(1-oxidopyridin-3-yl)methoxy]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl(2-{[4-(morpholin-4-ylmethyl)benzyl]oxy}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl{2-[(4-pyridin-2-ylbenzyl)oxy]pyrimidin-4-yl}acetonitrile;

1,3-benzothiazol-2-yl(2-{[4-(piperidin-1-ylmethyl)benzyl]oxy}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl[2-(4-methoxyphenoxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl[2-(4-butoxyphenoxy)pyrimidin-4-yl]acetonitrile;

{2-[4-(4-acetylpiperazin-1-yl)phenoxy]pyrimidin-4-yl}(1,3-benzothiazol-2-yl)acetonitrile;

[2-(4-methoxyphenoxy)pyrimidin-4-yl][5-(trifluoromethyl)-1,3-benzothiazol-2-yl]acetonitrile;

N-[2-({4-[1,3-benzothiazol-2-yl(cyano)methyl]pyrimidin-2-yl}amino)ethyl]-4-chlorobenzamide;

1,3-benzothiazol-2-yl(2-methoxy-4-pyrimidinyl)acetonitrile;

1,3-benzothiazol-2-yl[2-({4-[4-methylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl[2-({4-[(4-benzyl-piperazin-1-yl)methyl]-benzyl}oxy)pyrimidin-4-yl]acetonitrile;

1,3-benzothiazol-2-yl (2-{[4-(piperazin-1-ylmethyl)benzyl]oxy}pyrimidin-4-yl)acetonitrile;

1,3-benzothiazol-2-yl[2-({4-[(4-formylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl]acetonitrile;

[2-({4-[(4-acetylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl] (1,3-benzothiazol-2-yl)acetonitrile;

(3H-Benzothiazol-2-ylidene)-{2-[4-(4-[1,2,4]oxadiazol-3-ylmethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile;

4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid methyl ester;

2-[4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetamide;

(2-{4-[4-(2-Amino-acetyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-(3H-benzothiazol-2-ylidene)-acetonitrile;

[4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetic acid methyl ester;

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-methoxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile;

4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid dimethylamide;


(3H-Benzothiazol-2-ylidene)-{2-[4-(4-ethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile; and

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile.

Claims 9 and 10 (Cancelled).

11(Previously presented). The method according to claim 1, wherein n is 1 to 6.

12(Currently amended). A pharmaceutical composition comprising ~~an anti-diabetes agent and~~ a compound according to formula I:



as well as a tautomer, geometrical isomer, optically active form as enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt thereof, wherein

G is a pyrimidinyl group;

Appln. No. 10/571,291
Amd. dated June 15, 2011
Reply to Office Action of March 15, 2011

L is an C₁-C₆-alkoxy, an amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom selected from the group consisting of N, O, and S; and

R¹ is selected from the group consisting of hydrogen, sulfonyl, amino, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl or C₁-C₆-alkoxy, aryl, halogen, cyano and hydroxy.

13(Previously presented). A method for treating diabetes II, comprising administering an effective amount of the pharmaceutical composition according to claim 12 to a human or other mammal in need thereof.

Claims 14-20 (Cancelled).